-
1
-
-
33645526144
-
Cancer statistics, 2006
-
Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
-
(2006)
CA Cancer J Clin
, vol.56
, pp. 106-130
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
-
2
-
-
0036559864
-
A history of prostate cancer treatment
-
Denmeade S.R., and Isaacs J.T. A history of prostate cancer treatment. Nat Rev Cancer 2 (2002) 389-396
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 389-396
-
-
Denmeade, S.R.1
Isaacs, J.T.2
-
3
-
-
33845673431
-
Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues
-
Gomella L.G. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. BJU Int 99 Suppl 1 (2007) 25-29
-
(2007)
BJU Int
, vol.99
, Issue.SUPPL. 1
, pp. 25-29
-
-
Gomella, L.G.1
-
4
-
-
0033952191
-
Clinical states in prostate cancer: toward a dynamic model of disease progression
-
Scher H.I., and Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 55 (2000) 323-327
-
(2000)
Urology
, vol.55
, pp. 323-327
-
-
Scher, H.I.1
Heller, G.2
-
5
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
-
(2004)
N Engl J Med
, vol.351
, pp. 1502-1512
-
-
Tannock, I.F.1
de Wit, R.2
Berry, W.R.3
-
6
-
-
4744337716
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
-
Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
-
(2004)
N Engl J Med
, vol.351
, pp. 1513-1520
-
-
Petrylak, D.P.1
Tangen, C.M.2
Hussain, M.H.3
-
7
-
-
0019461193
-
Prostate tumor biology and cell kinetics-theory
-
Coffey D.S., and Isaacs J.T. Prostate tumor biology and cell kinetics-theory. Urology 17 (1981) 40-53
-
(1981)
Urology
, vol.17
, pp. 40-53
-
-
Coffey, D.S.1
Isaacs, J.T.2
-
8
-
-
0036682376
-
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer
-
Rhodes D.R., Barrette T.R., Rubin M.A., et al. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 62 (2002) 4427-4433
-
(2002)
Cancer Res
, vol.62
, pp. 4427-4433
-
-
Rhodes, D.R.1
Barrette, T.R.2
Rubin, M.A.3
-
11
-
-
33750807427
-
CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients
-
Miller A.M., Lundberg K., Ozenci V., et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177 (2006) 7398-7405
-
(2006)
J Immunol
, vol.177
, pp. 7398-7405
-
-
Miller, A.M.1
Lundberg, K.2
Ozenci, V.3
-
12
-
-
33748756028
-
TGF-beta: a mobile purveyor of immune privilege
-
Wahl S.M., Wen J., and Moutsopoulos N. TGF-beta: a mobile purveyor of immune privilege. Immunol Rev 213 (2006) 213-227
-
(2006)
Immunol Rev
, vol.213
, pp. 213-227
-
-
Wahl, S.M.1
Wen, J.2
Moutsopoulos, N.3
-
13
-
-
0141742297
-
Some interfaces of dendritic cell biology
-
Steinman R.M. Some interfaces of dendritic cell biology. APMIS 111 (2003) 675-697
-
(2003)
APMIS
, vol.111
, pp. 675-697
-
-
Steinman, R.M.1
-
14
-
-
34248204110
-
DC-based cancer vaccines
-
Gilboa E. DC-based cancer vaccines. J Clin Invest 117 (2007) 1195-1203
-
(2007)
J Clin Invest
, vol.117
, pp. 1195-1203
-
-
Gilboa, E.1
-
15
-
-
33748186518
-
Basic overview of current immunotherapy approaches in urologic malignancy
-
Drake C.G. Basic overview of current immunotherapy approaches in urologic malignancy. Urol Oncol 24 (2006) 413-418
-
(2006)
Urol Oncol
, vol.24
, pp. 413-418
-
-
Drake, C.G.1
-
16
-
-
33749606668
-
Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival
-
Thomas-Kaskel A.K., Zeiser R., Jochim R., et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer 119 (2006) 2428-2434
-
(2006)
Int J Cancer
, vol.119
, pp. 2428-2434
-
-
Thomas-Kaskel, A.K.1
Zeiser, R.2
Jochim, R.3
-
17
-
-
4344637057
-
Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study
-
Pandha H.S., John R.J., Hutchinson J., et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int 94 (2004) 412-418
-
(2004)
BJU Int
, vol.94
, pp. 412-418
-
-
Pandha, H.S.1
John, R.J.2
Hutchinson, J.3
-
18
-
-
33748142396
-
Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells
-
Lin A.M., Hershberg R.M., and Small E.J. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol 24 (2006) 434-441
-
(2006)
Urol Oncol
, vol.24
, pp. 434-441
-
-
Lin, A.M.1
Hershberg, R.M.2
Small, E.J.3
-
19
-
-
0034043167
-
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer
-
Burch P.A., Breen J.K., Buckner J.C., et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 6 (2000) 2175-2182
-
(2000)
Clin Cancer Res
, vol.6
, pp. 2175-2182
-
-
Burch, P.A.1
Breen, J.K.2
Buckner, J.C.3
-
20
-
-
0034554863
-
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
-
Small E.J., Fratesi P., Reese D.M., et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18 (2000) 3894-3903
-
(2000)
J Clin Oncol
, vol.18
, pp. 3894-3903
-
-
Small, E.J.1
Fratesi, P.2
Reese, D.M.3
-
21
-
-
33746012881
-
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
-
Small E.J., Schellhammer P.F., Higano C.S., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24 (2006) 3089-3094
-
(2006)
J Clin Oncol
, vol.24
, pp. 3089-3094
-
-
Small, E.J.1
Schellhammer, P.F.2
Higano, C.S.3
-
22
-
-
0027538181
-
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
-
Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90 (1993) 3539-3543
-
(1993)
Proc Natl Acad Sci U S A
, vol.90
, pp. 3539-3543
-
-
Dranoff, G.1
Jaffee, E.2
Lazenby, A.3
-
23
-
-
0032741439
-
Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
-
Simons J.W., Mikhak B., Chang J.F., et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59 (1999) 5160-5168
-
(1999)
Cancer Res
, vol.59
, pp. 5160-5168
-
-
Simons, J.W.1
Mikhak, B.2
Chang, J.F.3
-
24
-
-
0032543225
-
CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells
-
Adler A.J., Marsh D.W., Yochum G.S., et al. CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med 187 (1998) 1555-1564
-
(1998)
J Exp Med
, vol.187
, pp. 1555-1564
-
-
Adler, A.J.1
Marsh, D.W.2
Yochum, G.S.3
-
25
-
-
0030852624
-
Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells
-
Kurts C., Kosaka H., Carbone F.R., et al. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med 186 (1997) 239-245
-
(1997)
J Exp Med
, vol.186
, pp. 239-245
-
-
Kurts, C.1
Kosaka, H.2
Carbone, F.R.3
-
26
-
-
0346984033
-
A phase I/II trial of high dose allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer
-
[abstract]
-
Simons J.W., Higano C., Corman J., et al. A phase I/II trial of high dose allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer. [abstract]. Proc Am Soc Clin Oncol 22 (2003) 166
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
, pp. 166
-
-
Simons, J.W.1
Higano, C.2
Corman, J.3
-
27
-
-
34447650649
-
GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action
-
Simmons A.D., Li B., Gonzalez-Edick M., et al. GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action. Cancer Immunol Immunother 56 10 (2007) 1553-1565
-
(2007)
Cancer Immunol Immunother
, vol.56
, Issue.10
, pp. 1553-1565
-
-
Simmons, A.D.1
Li, B.2
Gonzalez-Edick, M.3
-
28
-
-
34447123763
-
Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
-
Small E.J., Sacks N., Nemunaitis J., et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13 (2007) 3883-3891
-
(2007)
Clin Cancer Res
, vol.13
, pp. 3883-3891
-
-
Small, E.J.1
Sacks, N.2
Nemunaitis, J.3
-
30
-
-
0032919654
-
Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer
-
Sanda M.G., Smith D.C., Charles L.G., et al. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53 (1999) 260-266
-
(1999)
Urology
, vol.53
, pp. 260-266
-
-
Sanda, M.G.1
Smith, D.C.2
Charles, L.G.3
-
31
-
-
0036787490
-
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer
-
Gulley J., Chen A.P., Dahut W., et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53 (2002) 109-117
-
(2002)
Prostate
, vol.53
, pp. 109-117
-
-
Gulley, J.1
Chen, A.P.2
Dahut, W.3
-
32
-
-
17444440950
-
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer
-
Eder J.P., Kantoff P.W., Roper K., et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6 (2000) 1632-1638
-
(2000)
Clin Cancer Res
, vol.6
, pp. 1632-1638
-
-
Eder, J.P.1
Kantoff, P.W.2
Roper, K.3
-
33
-
-
2942644684
-
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group
-
Kaufman H.L., Wang W., Manola J., et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 22 (2004) 2122-2132
-
(2004)
J Clin Oncol
, vol.22
, pp. 2122-2132
-
-
Kaufman, H.L.1
Wang, W.2
Manola, J.3
-
34
-
-
30544449854
-
A phase I trial of pox PSA vaccines (PROSTVAC(R)-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOMtrade mark) in patients with prostate cancer
-
Dipaola R., Plante M., Kaufman H., et al. A phase I trial of pox PSA vaccines (PROSTVAC(R)-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOMtrade mark) in patients with prostate cancer. J Transl Med 4 (2006) 1
-
(2006)
J Transl Med
, vol.4
, pp. 1
-
-
Dipaola, R.1
Plante, M.2
Kaufman, H.3
-
35
-
-
34447136106
-
Cancer vaccines: moving beyond current paradigms
-
Schlom J., Arlen P.M., and Gulley J.L. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 13 (2007) 3776-3782
-
(2007)
Clin Cancer Res
, vol.13
, pp. 3776-3782
-
-
Schlom, J.1
Arlen, P.M.2
Gulley, J.L.3
-
36
-
-
34748847470
-
Enhancing efficacy of therapeutic vaccinations by combination with other modalities
-
[epub ahead of print]
-
Gulley J.L., Madan R.A., and Arlen P.M. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine (2007) [epub ahead of print]
-
(2007)
Vaccine
-
-
Gulley, J.L.1
Madan, R.A.2
Arlen, P.M.3
-
37
-
-
2442585121
-
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
-
Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4 (2004) 336-347
-
(2004)
Nat Rev Immunol
, vol.4
, pp. 336-347
-
-
Chen, L.1
-
38
-
-
33646794392
-
Checkpoint blockade in cancer immunotherapy
-
Korman A.J., Peggs K.S., and Allison J.P. Checkpoint blockade in cancer immunotherapy. Adv Immunol 90 (2006) 297-339
-
(2006)
Adv Immunol
, vol.90
, pp. 297-339
-
-
Korman, A.J.1
Peggs, K.S.2
Allison, J.P.3
-
39
-
-
0035056017
-
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy
-
Chambers C.A., Kuhns M.S., Egen J.G., et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19 (2001) 565-594
-
(2001)
Annu Rev Immunol
, vol.19
, pp. 565-594
-
-
Chambers, C.A.1
Kuhns, M.S.2
Egen, J.G.3
-
40
-
-
27444440093
-
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer
-
Blansfield J.A., Beck K.E., Tran K., et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28 (2005) 593-598
-
(2005)
J Immunother
, vol.28
, pp. 593-598
-
-
Blansfield, J.A.1
Beck, K.E.2
Tran, K.3
-
41
-
-
34250223096
-
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
-
Small E.J., Tchekmedyian N.S., Rini B.I., et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13 (2007) 1810-1815
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1810-1815
-
-
Small, E.J.1
Tchekmedyian, N.S.2
Rini, B.I.3
-
42
-
-
3042592452
-
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy
-
Uchida J., Hamaguchi Y., Oliver J.A., et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199 (2004) 1659-1669
-
(2004)
J Exp Med
, vol.199
, pp. 1659-1669
-
-
Uchida, J.1
Hamaguchi, Y.2
Oliver, J.A.3
-
43
-
-
0242692683
-
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen
-
Nanus D.M., Milowsky M.I., Kostakoglu L., et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 170 (2003) S84-S88
-
(2003)
J Urol
, vol.170
-
-
Nanus, D.M.1
Milowsky, M.I.2
Kostakoglu, L.3
-
44
-
-
4344618391
-
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer
-
Milowsky M.I., Nanus D.M., Kostakoglu L., et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22 (2004) 2522-2531
-
(2004)
J Clin Oncol
, vol.22
, pp. 2522-2531
-
-
Milowsky, M.I.1
Nanus, D.M.2
Kostakoglu, L.3
-
45
-
-
22044451179
-
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
-
Bander N.H., Milowsky M.I., Nanus D.M., et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23 (2005) 4591-4601
-
(2005)
J Clin Oncol
, vol.23
, pp. 4591-4601
-
-
Bander, N.H.1
Milowsky, M.I.2
Nanus, D.M.3
-
46
-
-
20944441967
-
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer
-
Gulley J.L., Arlen P.M., Bastian A., et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 11 (2005) 3353-3362
-
(2005)
Clin Cancer Res
, vol.11
, pp. 3353-3362
-
-
Gulley, J.L.1
Arlen, P.M.2
Bastian, A.3
-
47
-
-
22144472230
-
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer
-
Arlen P.M., Gulley J.L., Todd N., et al. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol 174 (2005) 539-546
-
(2005)
J Urol
, vol.174
, pp. 539-546
-
-
Arlen, P.M.1
Gulley, J.L.2
Todd, N.3
-
48
-
-
33644760431
-
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer
-
Arlen P.M., Gulley J.L., Parker C., et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12 (2006) 1260-1269
-
(2006)
Clin Cancer Res
, vol.12
, pp. 1260-1269
-
-
Arlen, P.M.1
Gulley, J.L.2
Parker, C.3
-
49
-
-
33745612716
-
The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration
-
Prell R.A., Gearin L., Simmons A., et al. The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration. Cancer Immunol Immunother 55 (2006) 1285-1293
-
(2006)
Cancer Immunol Immunother
, vol.55
, pp. 1285-1293
-
-
Prell, R.A.1
Gearin, L.2
Simmons, A.3
-
50
-
-
36048969172
-
2007 ASCO Annual Meeting Proceedings, Part I
-
Gerritsen W.R. 2007 ASCO Annual Meeting Proceedings, Part I. J Clin Oncol 25 Suppl 18S0 (2007) 5120
-
(2007)
J Clin Oncol
, vol.25
, Issue.SUPPL. 18S0
, pp. 5120
-
-
Gerritsen, W.R.1
|